For Immediate Release

DIMERIX ANNOUNCES THE APPOINTMENT OF NON-EXECUTIVE CHAIRMAN TO THE BOARD

MELBOURNE, Australia, 20 November 2023: Dimerix Limited (ASX: DXB) ("Dimerix" or the "Company"), a clinical-stage biopharmaceutical company with late-stage clinical assets, today announced that Mr Mark Diamond has been appointed as Chair of the Board of Directors, effective 1 December 2023.

Mr Diamond is joining Dimerix at a very exciting time in the Company's evolution, as it progresses its global ACTION3 Phase 3 clinical trial in focal segmental glomerulosclerosis (FSGS), a rare type of kidney disease with first analysis outcomes expected in March 2024. In parallel, Dimerix completed its first regional licensing transaction in October 2023, and continues to make good progress on further licensing discussions for those other territories that remain available.

> "The board welcomes Mark to Dimerix as Chairman and we look forward to working with him as we continue to deliver on the global Phase 3 program, which include potential further commercial licensing transactions and a near term study outcome. Dimerix is fortunate to be able to gain access to the extensive expertise and networks Mark has across the sector. The board looks forward to Mark's contribution to the future of the Company."
>
> *Dimerix Board of Directors*

Mr Mark Diamond is a senior pharmaceutical executive with a demonstrated record of achievement and leadership over more than thirty years within the pharmaceutical and biotechnology industries. In May 2023, Mr Diamond retired from ASX listed Antisense Therapeutics Limited as Managing Director and CEO, a position he had held since 2001, making him at the time of his retirement the longest serving CEO of a publicly traded Healthcare Company on the ASX. At Antisense, Mr Diamond was responsible for and successful in capital raising initiatives, pipeline development, product out-licensing and clinical trial conduct among other significant accomplishments. Prior to his time at Antisense, Mr Diamond served in senior product and business development roles at Faulding Pharmaceuticals (now Pfizer) within their US, European and international pharmaceutical operations.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com

"I am pleased to have been appointed to Dimerix's Board of Directors as Chair. With its first major licensing transaction in place and initial analysis outcome from its ACTION3 Phase 3 clinical trial in FSGS patients anticipated in March 2024, Dimerix has entered a new commercialisation era. I look forward then to working with the Dimerix Board and leadership team as the Company moves into this new chapter of corporate growth and development." *Mark Diamond, In-coming Dimerix Non-Executive Chairman*

Mr Diamond holds a Bachelor of Science degree from Monash University and an MBA from Macquarie University.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on **LinkedIn** and **Twitter**

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA® in some territories), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-700 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

About FSGS

FSGS is a rare disease that attacks the kidney's filtering units, where blood is cleaned (called the 'glomeruli'), causing irreversible scarring. This leads to permanent kidney damage and eventual end-stage failure of the organ, requiring dialysis or transplantation. For those diagnosed with FSGS the prognosis is not good. The average time from a diagnosis of FSGS to the onset of complete kidney failure is only five years and it affects both adults and children as young as two years old.[1] For those who are fortunate enough to receive a kidney transplant, approximately 60% will get re-occurring FSGS in the transplanted kidney.[2] At this time, there are no drugs specifically approved for FSGS anywhere in the world, so the treatment options and prognosis are limited.

FSGS is a billion-dollar plus market: the number of people with FSGS in the US alone is just over 80,000,[1] and worldwide about 220,000.[3] The illness has a global compound annual growth rate of 8%, with over 5,400 new cases diagnosed in the US alone each year.[4] Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX 200 in both the US and Europe for FSGS. Orphan Drug Designation is granted to support the

development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and a fast-tracked regulatory pathway to approval. Dimerix reported positive Phase 2a data in FSGS patients in July 2020.

References

1 *Guruswamy Sangameswaran KD, Baradhi KM. (2021) Focal Segmental Glomerulosclerosis), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/*

2 *Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669*

3 *Delve Insight Market Research Report (2022): Focal segmental glomerulosclerosis (FSGS) – Market Insight, Epidemiology and market forecast – 2032; https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market;*

4 *Nephcure Kidney International (2020); Focal Segmental Glomerulosclerosis, online https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/understanding-fsgs/*